K. Bergethon

发表

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2011, Science Translational Medicine.

ROS1 rearrangements define a unique molecular class of lung cancers.

Jeffrey W. Clark, Julie M. Batten, A. Iafrate, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2012 .

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2013 .

Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry.

Adrian F Hernandez, Deepak L. Bhatt, Deepak L Bhatt, 2016, Circulation. Heart failure.

Introduction, Cancellation, and Future Promise of Medicare Cardiac Episode Payment Models

K. Bergethon, J. Wasfy, 2018, Circulation. Cardiovascular quality and outcomes.

A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas

A. Iafrate, D. Rakheja, D. Dias-Santagata, 2011, Modern Pathology.

Activation of PI3K Signaling in Merkel Cell Carcinoma

A. Iafrate, J. Engelman, J. Settleman, 2012, Clinical Cancer Research.

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas

Y. Yagi, A. Iafrate, V. Klepeis, 2012, Modern Pathology.

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

Julie M. Batten, A. Iafrate, K. Flaherty, 2012, Clinical Cancer Research.

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

A. Iafrate, J. Engelman, J. Settleman, 2010, Science Signaling.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activation of PI 3 K Signaling in Merkel Cell Carcinoma

A. Iafrate, J. Engelman, J. Settleman, 2012 .

The physical basis of biochemistry : the foundations of molecular biophysics

P. R. Bergethon, K. Bergethon, P. Bergethon, 1998 .

The Interplay between Financial Incentives, Institutional Culture, and Physician Behavior: An Incompletely Understood Relationship Worth Elucidating.

K. Bergethon, Daniel M. Blumenthal, 2018, Journal of hospital medicine.

The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma

A. Iafrate, M. Mino‐Kenudson, D. Dias-Santagata, 2011, Modern Pathology.

Inactivation of the tumor suppressor WTX in a subset of pediatric tumors

A. Iafrate, M. Rivera, Yunqing Ma, 2014, Genes, chromosomes & cancer.

Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.

A. Iafrate, J. Engelman, K. Bergethon, 2010 .

Activation of PI3K Signaling in Merkel Cell Carcinoma

A. Iafrate, J. Engelman, J. Settleman, 2012, Clinical Cancer Research.